Format

Send to

Choose Destination
Curr Opin Oncol. 2013 Jan;25(1):44-9. doi: 10.1097/CCO.0b013e32835a448c.

New targeted therapies and other advances in the management of anaplastic thyroid cancer.

Author information

1
Department of Medicine, Section of Medical Oncology, Yale University, New Haven, Connecticut 06520, USA. Hari.deshpande@yale.edu

Abstract

PURPOSE OF REVIEW:

Anaplastic thyroid cancer is the most aggressive solid tumor known to humans. Even when found in a localized form, the prognosis is grave. For metastatic disease, there has been little effect on survival using traditional chemotherapy.

RECENT FINDINGS:

Over a five-decade interval, there has been little progress in the treatment of this malignancy. However, targeted agents represent a new mode of treatment, and some studies have shown encouraging preclinical results. Combretastatin has shown activity in phase 1 and phase II trials; although the registration phase III study failed to meet its accrual goals, it did appear to show some benefit, especially in younger patients.

SUMMARY:

Combinations of this compound and other targeted agents may prove to be a breakthrough in an otherwise untreatable cancer.

PMID:
23159847
DOI:
10.1097/CCO.0b013e32835a448c
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center